Frederic Rolland
Overview
Explore the profile of Frederic Rolland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
6763
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fayette J, Even C, Digue L, Geoffrois L, Rolland F, Cupissol D, et al.
BMJ Oncol
. 2025 Jan;
2(1):e000065.
PMID: 39886516
Objective: Salivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary...
2.
Fizazi K, Le Teuff G, Flechon A, Pagliaro L, Mardiak J, Geoffrois L, et al.
J Clin Oncol
. 2024 Aug;
42(28):3270-3276.
PMID: 39167741
JCO GETUG-13 established that switching patients with poor-prognosis nonseminomatous germ-cell tumors with an unfavorable marker decline to intensified chemotherapy resulted in improved outcomes. Here, we report the GETUG-13 long-term efficacy...
3.
Rajpar S, Ibrahim T, Carmel A, Merabet Z, Vielh P, Foulon S, et al.
Eur Urol Oncol
. 2024 Jul;
PMID: 39034169
Background And Objective: Docetaxel has become a standard component of care for advanced prostate cancer (PC); however, its benefits are not universal among patients. A subset of PC cases exhibit...
4.
Blay J, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, et al.
Eur J Cancer
. 2024 Jul;
208:114228.
PMID: 39018632
Rationale: We report a phase II trial (OSAD93) testing CDDP with ifosfamide (IFO), without doxorubicin in neoadjuvant phase, in adult osteosarcoma with a 25 years follow-up. Patients And Methods: This...
5.
Guigay J, Le Caer H, Ferrand F, Geoffrois L, Saada-Bouzid E, Fayette J, et al.
Lancet Healthy Longev
. 2024 May;
5(6):e392-e405.
PMID: 38759667
Background: A standard treatment for fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is yet to be established. In the previous EXTREME trial, few...
6.
Naffrichoux J, Poupin P, Pouillot W, Linassier C, Rioux-Leclercq N, De Vries-Brilland M, et al.
Eur J Cancer
. 2024 May;
205:114121.
PMID: 38749111
Introduction: Papillary renal cell carcinoma (pRCC) is a rare and aggressive cancer with no specifically established therapeutic strategy in the metastatic setting. Combinations of tyrosine kinase and immune checkpoint inhibitors...
7.
Mourey L, Rainho L, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, et al.
Eur J Cancer
. 2024 Feb;
201:113589.
PMID: 38382153
Introduction: Immune checkpoint inhibitors are standard of care in metastatic renal cell carcinoma but their activity and safety in elderly patients is insufficiently explored. We evaluated outcomes of elderly patients...
8.
Lin C, Garralda E, Schoffski P, Hong D, Siu L, Martin M, et al.
Oncoimmunology
. 2024 Jan;
13(1):2290787.
PMID: 38170160
Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the...
9.
Marret G, Temam S, Kamal M, Even C, Delord J, Hoffmann C, et al.
Sci Rep
. 2023 Dec;
13(1):22524.
PMID: 38110561
There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of...
10.
De Vries-Brilland M, Rioux-Leclercq N, Meylan M, Dauve J, Passot C, Spirina-Menand E, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 37935564
Background: Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC, and associated with poor outcomes in the metastatic setting. In this study, we aimed to comprehensively evaluate...